Pfizer DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.74×	0.74×	0.76×	0.74×	0.76×
	1.12×	1.15×	1.50×	1.30×	1.17×
	34.4%	33.6%	29.8%	26.1%	29.0%
	0.51×	0.51×	0.50×	0.53×	0.61×
	1.17×	1.17×	1.16×	1.18×	1.25×
	17.1%	17.1%	19.6%	15.7%	19.6%
	17.2%	17.2%	19.7%	16.2%	19.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PFIZER₹3,734.40

Pfizer Ltd.

· Pharma & Health

₹ CrorePeersGLAXO ABBOTINDIA POLYMED ONESOURCE RAINBOW KIMS JUBLPHARMA VIJAYA

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.76	0.74	0.76	0.74	0.74
Interest Burden (Pretax/EBIT) ×	1.17	1.30	1.50	1.15	1.12
EBIT Margin %	29.01	26.13	29.78	33.59	34.40
Asset Turnover ×	0.61	0.53	0.50	0.51	0.51
Financial Leverage (Assets/Equity) ×	1.25	1.18	1.16	1.17	1.17
ROE (5-step product, year-end total equity) %	19.58	15.67	19.59	17.12	17.09
ROE (owners' profit / average owners' equity) %	19.45	16.21	19.65	17.16	17.16

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.